December 2023 PRECISION1 One-Third Interim Analysis PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity Across Multiple Solid Tumors with TSC1 or TSC2 Inactivating Alterations Exhibit 99.2

Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management’s intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. Forward-looking statements may include, without limitation, statements regarding: the anticipated timing of commencement, enrollment, data releases and completion of clinical trials of Aadi Bioscience, Inc. (“Aadi”), including the expected full enrollment of the PRECISION 1 trial by spring of 2024, the expected PRECISION 1 two-thirds interim analysis in 3Q 2024, the anticipated completion of the PRECISION1 study by the end of 2024, and the final PRECISION1 data readout anticipated in early 2025; management’s belief that the Company is on track to generate additional clinical evidence in the PRECISION 1 study and for advancing nab-sirolimus toward registration; the timing and likelihood of regulatory filings and approvals of FYARRO for new indications; the anticipated timing for potential catalysts based on data for Aadi’s clinical trials; Aadi’s anticipated cash runway; Aadi’s potential to become a leading precision oncology company; and projected annual incidence of cancers with TSC1 & TSC2 alterations and related market opportunities. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Aadi uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, uncertainties associated with the clinical development and regulatory approval of FYARRO, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the release of interim, topline and preliminary data from clinical trials; Aadi’s plans to develop and commercialize FYARRO® (nab-sirolimus, ABI-009); Aadi’s commercialization, marketing and manufacturing capabilities and strategy; the clinical utility, potential benefits and market acceptance of FYARRO; risks related to the sufficiency Aadi’s cash balance to fund operations; Aadi’s plans to research, develop and commercialize its current and future product candidates; Aadi’s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to market size, Aadi’s competitors and its industry; the impact of government laws and regulations; Aadi’s ability to protect its intellectual property position; and Aadi’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. These risks are described in detail under the caption “Risk Factors” in Aadi’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2023, and other documents filed from time to time with the SEC. Forward-looking statements included in this presentation are based on information available to Aadi as of the date of this presentation. Except as required by law, Aadi undertakes no obligation to revise or update any forward-looking statement, whether as a result of new information, future events or otherwise.

Populations Phase 1 Phase 2 Approved Current Status Advanced Malignant PEComa, AMPECT Clinical Trial First FDA approved therapy for advanced malignant PEComa Pan-Tumor TSC1 / TSC2 Inactivating Alterations Registration directed tumor-agnostic pivotal study in nab-sirolimus with independent arms for TSC1 or TSC2 inactivating alterations; Open for enrollment Pan-Tumor TSC2 Inactivating Alterations Advanced or recurrent endometrial cancer Trial combining nab-sirolimus with letrozole for patients with endometrioid-type endometrial carcinoma; Open for enrollment Neuroendocrine tumors (NETs) Utilizing nab-sirolimus as a monotherapy in neuroendocrine tumors; Open for enrollment Advanced solid tumors or NSCLC with KRASG12C mutation Ongoing collaboration with Open for enrollment Aadi Bioscience Advanced Oncology Development Pipeline

TSC1 and TSC2 Alterations: Key Oncogenic Drivers in the mTOR Pathway mTOR Signaling Pathway mTOR S6K 4EBP1 Rheb Raptor PDK1 AMPK Akt TSC1/ TSC2 LKB1 (STK11) ERK MEK Raf Ras Inactivating mutations in TSC1 and TSC2 drive mTOR pathway activation and tumor growth TSC1 and TSC2 are upstream regulators of mTOR activity within the PI3K/Akt/mTOR pathway TSC1 and TSC2 mutations occur at a rate of ~2% across cancers or ~16,000 new cases each year No approved therapies for TSC1 and TSC2 mutant patients but numerous case reports with durable responses to mTOR inhibition Standard CLIA-certified NGS panels already capture TSC1 and TSC2 mutations Frequently mutated in cancer and/or validated target

Next generation sequencing (NGS) of nearly 440,000 cancer patients from the Foundation Medicine database 2% of patients have known or likely inactivating alterations in TSC1 or TSC2 Based on extrapolation from SEER database, ~16,000 new cancer cases each year would have actionable TSC1 or TSC2 alterations 1 Kwiatkowski, MD. Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database. Poster presented at: EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA). Boston, MA; October 11-15, 2023 Note: Methodology to determine TAM consists of applying FMI RW data (TSC1/2 mutation frequency) presented at AACR-NCI-EORTC and incident cancer volume for solid tumors in the SEER database (2023) Real-World Analysis of TSC1 and TSC2 Patient Population1 Approximately 16,000 patients with TSC1 or TSC2 inactivating alterations across varying tumor types represent a potential multi billion-dollar total addressable market in each alteration Tumor Clusters % Patients (n=16,000) TSC1 and TSC2 Inactivating Alterations Represent Significant Opportunity Across Common Cancer Types Alteration Split Patients (n=16,000) TSC1 8,500

Data from AMPECT in TSC1 or TSC2 Inactivating Alterations Supports Further Investigation Across Different Tumor Types Note: *1 patient with TSC2 mutation had an unconfirmed PR and thus best response is an SD as per RECIST 1.1; Source: AJ Wagner et al., JCO. 2021 TSC2 mutation TSC1 mutation No TSC1 or TSC2 mutation UNK mutational status 25 patients had available NGS reports Confirmed Responders: 9/14 (64%) pts with TSC1/TSC2 vs 1/11 (9%) with no TSC1/TSC2 alterations TSC1/TSC2: 12/14 (86%) patients had Disease Control (CR or PR or SD ≥12 weeks) Best Overall Responses Patients with NGS* (N=25) TSC1/TSC2 Non TSC1/TSC2 n = 14 n = 11 Complete or Partial Response 9/14 (64%) 1/11 (9%) Stable Disease 4/14 (29%) 8/11 (73%) Stable Disease ≥12 weeks 3/14 (21%) 5/11 (45%) Progressive Disease 1/14 ( 7%) 2/11 (18%)

PRECISION1: Registration Directed Tumor-Agnostic Trial of nab-sirolimus in TSC1 or TSC2 Inactivating Alterations (N = ~60) (N = ~60) Arm A: TSC1 Arm B: TSC2 Key Eligibility Criteria Metastatic or locally advanced disease ineligible for surgery Naïve to mTOR inhibitor treatment Pathogenic TSC1 or TSC2 inactivating alterations identified through NGS Must have received standard therapy for the disease or in investigator opinion unlikely to benefit PRECISION1 Trial Two independently evaluable arms, one each for TSC1 and TSC2 Primary endpoint: ORR by blinded, independent radiologic review Patient accrual based on local NGS results First patient dosed March 2022 with expected 24-month enrollment period

PRECISION1: Demographics, Efficacy Evaluable Population 1 Three patients without post-baseline assessment not included; all three patients received two or fewer doses and none withdrew due to treatment-related adverse events TSC1 n=191 TSC2 n=18 Age median (range) 64 (37-72) 62 (28-82) M/F 5 / 14 7 / 11 PRIOR Rx median (range) ≥ 3rd Line (%) ≥ 5th Line (%) 3 (0-7) 15 (79) 5 (26) 3.5 (1-7) 15 (83) 9 (50) ECOG 0 1 7 12 8 10 Different tumor types 9 13

PRECISION1: Tumor Types Enrolled in Arms A (TSC1) and B (TSC2) Tumor TSC 1 n=19 TSC 2 n=18 Bladder 4 0 Ovary 3 2 Endometrial 3 0 Colon 3 1 Leiomyosarcoma 2 2 Breast 1 3 Cervix 1 1 Adrenocortical 1 0 Hepatocellular 1 1 Soft Tissue Sarcomas 0 2 GIST 0 1 PNET 0 1 Vaginal 0 1 Osteosarcoma 0 1 Mesothelioma 0 1 Head & Neck 0 1

TSC1 Inactivating Alterations: Efficacy Efficacy Evaluable1 (N=19)2 Response Partial Response3 (n, %) 5 (26) Stable Disease (SD) (n, %) SD SD ≥ 6 mos 9 (47) 3 (16) Progressive Disease (PD) (n,%) 5 (26) Clinical Benefit Rate (n,%) (PR+SD ≥ 6 mos) 8 (42) Duration of Response (median) NE Time to Response Median – mos 1.4 1 By Investigator Assessment 2 Three patients without post-baseline assessment not included 3 One unconfirmed PR, patient on treatment and awaiting confirmatory scan

3 mos 6 mos 9 mos 12 mos Initiation of Response Ongoing TSC1 Inactivating Alterations: Patient Time on Treatment

TSC1 Inactivating Alterations: Best Overall Response Tumor reduction observed in 79% of patients + + + + + + + indicates ongoing

TSC1 Inactivating Alterations: Investigator-Assessed Efficacy Observations ORR of 26% encouraging 5 Responses seen in 4 different epithelial carcinoma types Heavily pre-treated population Median of 3 prior lines of therapy Responses appear to be early, deep and durable All are ongoing; more than half have >50% reduction

Efficacy Evaluable1 (N=18) Response Partial Response2 (n, %) 2 (11) Stable Disease (n, %) SD SD ≥ 6 mos 12 (67) 3 (17) Progressive Disease 4 (22) Clinical Benefit Rate (PR+SD ≥ 6 mos) 5 (28) Duration of Response (median) NE Time to Response (mo) 3.6 TSC2 Inactivating Alterations: Efficacy 1 By Investigator Assessment 2 One unconfirmed PR with a single PR assessment

TSC2 Inactivating Alterations: Patient Time on Treatment

TSC2 Inactivating Alterations: Best Overall Response Tumor reduction observed in 61% of patients + + + + + indicates ongoing

TSC2 Inactivating Alterations: Investigator-Assessed Efficacy Observations ORR 11% (2/18) Responses seen in epithelial carcinoma and sarcoma CBR 28% (2 PR + 3 SD >6 mos) Population was heavily pre-treated 9/18 are ≥ 5th line

PRECISION1: Safety Conclusions No new safety signals Pattern of AEs consistent with nab-sirolimus label and mTORi class No grade 4 TRAEs or deaths due to study drug 1 patient discontinued study due to grade 2 recurrent pneumonitis

PRECISION1 Interim Analysis Summary TSC1 arm results encouraging Response rate in range of our expectations Responses appear to be deep and durable in a heavily pre-treated population Responses in different tumor types supportive of a tumor agnostic indication TSC2 arm ORR interpretation is complicated by small sample size and heavy pre-treatment 50% patients received 5 or more prior therapies Two-third interim enrollment of 80 patients completed

Initial Interim Analysis Completed and Upcoming PRECISION1 Milestones PRECISION1 Key Milestones Full Enrollment and Two-Thirds Interim Analysis PRECISION1 Trial Completion 2024: PRECISION1 trial full enrollment expected in Spring of 2024 PRECISION1 two-thirds interim analysis expected in 3Q24 Anticipated completion of PRECISION1 trial by YE 2025: Results of PRECISION1 trial of 120 patients expected in early 2025 2023 2024 2025 Tumor Agnostic TSC1 & TSC2 Alterations ~16,000 US Patients/yr 2023: PRECISION1 tumor agnostic TSC1/2 one-third interim analysis on 40 patients Enrollment for 2/3 interim (80 patients) completed PRECISION1 Trial Readout

Thank You NASDAQ: AADI www.aadibio.com